In addition, administration of RGFP966 via intraperitoneal injection displayed ameliorated disease severity in our study, suggesting that it's feasible to target CX3CR1 positive monocytes HDAC3 for colitis therapy with little effect on IEC HDAC3 by changing the administration route of HDAC3 inhibitor. The gene discussed is CX3CR1; the disease is colitis.